-
1 Comment
Shanghai Junshi Biosciences Co., Ltd is currently in a long term downtrend where the price is trading 14.2% below its 200 day moving average.
From a valuation standpoint, the stock is 68.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 35.5.
Shanghai Junshi Biosciences Co., Ltd's total revenue rose by 23.4% to $575M since the same quarter in the previous year.
Its net income has dropped by 31.5% to $-598M since the same quarter in the previous year.
Finally, its free cash flow grew by 72.3% to $-568M since the same quarter in the previous year.
Based on the above factors, Shanghai Junshi Biosciences Co., Ltd gets an overall score of 3/5.
| Exchange | HK |
|---|---|
| CurrencyCode | HKD |
| ISIN | CNE100003FF7 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Market Cap | 27B |
|---|---|
| PE Ratio | None |
| Target Price | 15.7841 |
| Beta | 0.63 |
| Dividend Yield | None |
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of malignant tumors, neurological, autoimmune, chronic metabolic, nervous system, and infectious diseases in the People's Republic of China. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 1877.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
